Fig. 2
From: Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Association of TSH increase to treatment response. On day-15 there was a mean increase × 2.52 the baseline value (paired t-test p < 0.00001) and on day-75 (by end of cycle 2) × 3.68 the baseline value (paired t-test p < 0.00001). TSH increased earlier (day-15) in patients that exhibited a response: × 1.59 times in PD patients, × 2.18 times in SD patients and × 3.33 times in PR patients on day-15. These differences were less prominent on day-75 (× 3.29, × 3.41, and × 3.96 respectively). The data suggest that early increase in TSH levels may predict clinical benefit from sunitinib in mRCC patients